NovaBridge Biosciences
NBPNasdaq
$1.78
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↓ -17.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$392.1M
Enterprise Value
$163.8M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$46.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-17.9%
ROIC
-243.0%
Debt / Equity
—
Net Cash
$228.3M
Return 1Y
-17.6%
Company profile
I-Mab discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases. Its product candidates also includes Enoblituzumab, which has completed Phase 2 clinical trials for head and neck cancer, and other oncology diseases.
- CEO
- Xiu X. Zhu
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 380
- Headquarters
- Maryland
- Website
- i-mabbiopharma.com
Management & directors
- Xu Cong ClaireSVP, Clinical Development
- Dennis Phillip AndrewChief Medical Officer
- Cao Sean WuxiongSee Remarks
- Hagler Mark ArnoldSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
NBP Q3 2025 Earnings
Period ends 2025-09-30
MetricActualYoY
Revenue——
Diluted EPS-$0.03↓ -72.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $236.4M | $13.8M | -$1.6M | $632,000.00 | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | -$53.1M | -$72.0M | -$51.4M | -$94.3M |
| Net income | $72.2M | -$365.9M | -$371.1M | -$207.7M | -$22.2M | -$46.3M |
| Diluted EPS | $0.46 | -$2.09 | -$1.96 | -$1.09 | -$0.12 | -$0.21 |
| Operating cash flow | $66.4M | -$152.7M | -$159.9M | -$183.8M | — | — |
| Free cash flow | $65.2M | -$157.4M | -$162.0M | -$184.0M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | 3422.2% | -11395.1% | — | — |
| Net margin | 30.5% | -2648.7% | 23923.5% | -32868.5% | — | — |
| Line item | Q3 '24 | Q3 '25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$12.4M | -$9.0M |
| Net income | -$20.5M | -$6.8M |
| Diluted EPS | -$0.11 | -$0.03 |
| Operating cash flow | — | — |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Jun 29, 2026
May 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Xu Cong Claire· SVP, Clinical Development | Sale | 4,485 | $0.89 | $3,991.65 | filing |
| 2026-07-04 | Xu Cong Claire· SVP, Clinical Development | Option exercise | 12,432 | — | — | filing |
| 2026-06-18 | Dennis Phillip Andrew· Chief Medical Officer | Sale | 8,494 | $0.66 | $5,606.04 | filing |
| 2026-06-17 | Dennis Phillip Andrew· Chief Medical Officer | Option exercise | 23,695 | — | — | filing |
| 2026-06-01 | Xu Cong Claire· SVP, Clinical Development | Sale | 3,494 | $3.94 | $13,766.36 | filing |
| 2026-05-30 | Xu Cong Claire· SVP, Clinical Development | Option exercise | 9,382 | — | — | filing |
| 2026-05-14 | Cao Sean Wuxiong· See Remarks | Sale | 21,399 | $1.99 | $42,584.01 | filing |
| 2026-04-24 | Hagler Mark Arnold· See Remarks | Buy | 230,000 | $2.51 | $577,300.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.